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Abstract
Background: Ovarian cancer is the leading cause of death among gynecological cancers. Cisplatin is one of the most 
effective anticancer drugs used in the treatment of ovarian cancer. Development of resistance to cisplatin limits its 
therapeutic use. Most of the anticancer drugs, including cisplatin, are believed to kill cancer cells by inducing apoptosis 
and a defect in apoptotic signaling can contribute to drug resistance. The tumor suppressor protein p53 plays a critical 
role in DNA damage-induced apoptosis. During a yeast-based drug screening, NSC109268 was identified to enhance 
cellular sensitivity to cisplatin. The objective of the present study is to determine if p53 is responsible for cisplatin 
sensitization by NSC109268.
Results: NSC109268 enhanced sensitivity of ovarian cancer 2008 cells and its cisplatin resistant counterpart 2008/C13* 
cells which express wild-type p53. The potentiation of cisplatin sensitivity by NSC109268 was greater in 2008/C13* cells 
compared to 2008 cells. Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and 
the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. NSC109268 
alone had no effect on p53 but it enhanced p53 level in response to cisplatin. Knockdown of p53 by siRNA, however, 
did not attenuate cell death in response to cisplatin or combination of NSC109268 and cisplatin.
Conclusions: These results demonstrate that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin 
independent of p53.
Background
cis-Diamminedichloroplatinum(II) or cisplatin is one of
the most important anticancer drugs used in the treat-
ment of solid tumors, especially ovarian, testicular, cervi-
cal and small cell lung carcinomas. Dose-limiting toxicity
to normal tissues and acquisition of resistance by tumor
tissues to cisplatin, however, poses a significant problem
in cisplatin therapy. Identification of agents that can sen-
sitize tumor cells to cisplatin, and circumvent or prevent
cisplatin resistance should have significant impact in cis-
platin-based therapy.
The anticancer activity of cisplatin is believed to be due
to its interaction with chromosomal DNA [1]. However,
only a small fraction of cisplatin actually interacts with
DNA, and inhibition of DNA replication cannot solely
account for its biological activity [2]. The effectiveness of
anticancer agents depends not only on their ability to
induce DNA damage but also on the cell's ability to detect
and respond to DNA damage [3,4]. The tumor suppressor
protein p53 plays a critical role in DNA damage signaling
[5]. It is activated in response to DNA damage and trig-
gers transcription of genes involved in cell cycle, apopto-
sis, senescence and DNA repair [6,7]. The p53 gene is
mutated in 50% of human cancers, and it is often inacti-
vated by oncogenic viruses in those cases in which p53 is
not mutated [8-10]. For example, the majority of cervical
cancer cells contain wild-type p53 but the E6 gene prod-
uct of human papilloma virus (HPV) results in the rapid
degradation of p53 through the ubiquitin proteasome
pathway [10]. Thus, these cells have the same functional
consequences as a mutated p53 gene.
NSC109268 was found to enhance sensitivity of bud-
ding yeast Saccharomyces cerevisiae during a novel yeast-
based genetic screening of the Diversity Set compound
library provided by the Developmental Therapeutics
Division (NCI). It also increased sensitivity of human
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cancer cells to cisplatin [11]. In the present study, we have
examined the ability of NSC109268 to sensitize parental
and cisplatin-resistant variants of p53-positive ovarian
carcinoma 2008 and p53-null human cervical carcinoma
HeLa cells to cisplatin. NSC109268 enhanced sensitivity
of human ovarian carcinoma 2008 cells to cisplatin but it
had no effect on the sensitivity of HeLa cells. However ,
the mechanism of cisplatin sensitization by NSC109268
did not involve p53.
Results
Effect of NSC109268 on cisplatin sensitivity
We compared the ability of NSC109268 to sensitize
human ovarian cancer 2008 and human cervical cancer
HeLa cells and their cisplatin-resistant counterparts
HeLa/CP and 2008/C13* cells, respectively. Figure 1
shows that NSC109268 enhanced the sensitivity of both
parental 2008 cells and cisplatin-resistant variant 2008/
C13* cells to cisplatin although the effect was more pro-
nounced with 2008/C13* cells. When 2008 cells were
treated with different concentrations of cisplatin alone
for 72 h, the IC50 for cisplatin was 0.8 μM and it decreased
to 0.5 μM when treated with both NSC109268 and cispla-
tin. The IC50 of 2008/C13* cells for cisplatin was greater
than 10 μM and decreased to 2.8 μM when NSC109268
was included with cisplatin. In contrast, NSC109268 did
not influence the sensitivity of parental HeLa and cispla-
tin-resistant variant HeLa/CP cells to cisplatin (Figure 2).
Thus, NSC109268 enhanced the sensitivity of p53-posi-
tive ovarian cancer 2008 cells, and it had greater effect on
cisplatin-resistant variant compared to parental drug-
sensitive cells.
Effect of NSC109268 on cisplatin-induced p53 level
Since p53 plays a critical role in DNA damage signaling,
we compared the effects of cisplatin on the cleavage of
PARP and p53 induction in 2008 and 2008/C13* cells.
Figure 3 shows that cisplatin caused a concentration-
dependent increase in PARP cleavage in 2008 cells but
not in 2008/C13* cells. Cisplatin also caused a concentra-
tion-dependent increase in p53 level in both 2008 and
2008/C13* cells but much higher concentrations of cispl-
atin were required to induce p53 in 2008/C13* cells com-
pared to 2008 cells. Thus, the induction of p53 by
cisplatin was associated with an increase in cisplatin-
induced apoptosis in 2008 cells as determined by the
cleavage of PARP. 2008/C13* cells were resistant to cispl-
atin-induced apoptosis.
To determine if NSC109268 sensitizes these ovarian
carcinoma cells to cisplatin via p53-dependent mecha-
nisms, we treated 2008 and 2008/C13* cells with the
combination of NSC and cisplatin, and monitored p53
level and PARP cleavage. In this experiment, we treated
2008 and 2008/C13* cells with 1 μM and 40 μM cisplatin,
respectively that had no effect on PARP cleavage at 24 h
(Figure 3). As shown in Figure 4, cisplatin caused a sub-
stantial increase in p53 in both 2008 and 2008/C13* cells
but NSC109268 alone had little effect on p53 induction.
A 24 h treatment with NSC109268 and cisplatin caused a
modest increase in p53 in 2008/C13* cells but not in 2008
cells. A 48 h treatment with NSC109268 and cisplatin
increased p53 in both 2008 and 2008/C13* cells but the
effect was more pronounced in 2008/C13* cells. A 24 h
treatment with cisplatin had little effect on PARP cleav-
age even when coincubated with 2 μM and 3 μM
NSC109268. A 48 h treatment of 2008 cells with 1 μM
Figure 1 The effects of NSC109268 on the sensitivity of parental (2008) and cisplatin-resistant (2008/C13*) ovarian cancer cells to cisplatin. 
Cells were treated without (open circle) or with 2 μM NSC109268 (black circle) and varying concentrations of cisplatin for 72 h. Cell survival was de-
termined by the MTT assay. The control values were based upon the results obtained in the absence of any drug but in the presence of vehicle or 2 
μM NSC109268. Each value represents the mean ± SD of four determinants from a single microtiter plate. The results are representative of three inde-
pendent experiments.
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cisplatin caused PARP cleavage, which increased mod-
estly by the inclusion of NSC109268. While 48 h treat-
ment of 2008/C13* cells with 40 μM cisplatin alone had
no effect on the cleavage of PARP, the combination of
NSC109268 and cisplatin induced cleavage of PARP in
2008/C13* cells.
We also examined the effect of NSC109268 on cispla-
tin-induced cell death by staining cells with Yo-Pro-1 and
propidium iodide (PI). The green-fluorescent dye Yo-Pro-
1 can enter apoptotic cells, whereas the red fluorescent
dye PI can only ent er dead ce lls. T hus, when ce lls are
stained with both Yo-Pro-1 and PI, apoptotic cells show
green fluorescence whereas dead cells show primarily red
fluorescence and some green fluorescence. As shown in
Figure 5, NSC109268 enhanced cisplatin-induced cell
death in 2008/C13* cells but had only a modest effect on
cisplatin-induced cell death in 2008 cells.
Effect of p53 knockdown on the sensitization of cisplatin-
induced cell death in 2008/13* cells
To determine if potentiation of cisplatin-induced cell
death by NSC109268 was due to upregulation of p53 in
2008/13* cells, we examined the consequence of p53
depletion on the effects of NSC109268 on PARP cleavage
and cell death triggered by cisplatin. Figure 6A shows that
knockdown of p53 by siRNA effectively depleted p53 and
little p53 could be detected following treatment with cis-
platin. p53 was induced following treatment with
NSC109268 and cisplatin even when cells were trans-
fected with p53 siRNA albeit at much lower level com-
pared to cells transfected without or with control siRNA.
However, knockdown of p53 had little effect on cisplatin
sensitivity or potentiation of cisplatin-induced PARP
cleavage.
We also monitored cell death by staining cells with Yo-
Pro-1 and PI staining (Figure 6B). Knockdown of p53
failed to prevent cisplatin-induced cell death in 2008/
C13* cells. If anything, p53 depletion caused a slight
increase in cisplatin-induced cell death. Moreover, p53
knockdown had no effect on the potentiation of cisplatin-
induced cell death by NSC109268. Thus, NSC109268
enhanced cisplatin-induced cell death via p53-indepen-
dent pathway.
Figure 2 The effects of NSC109268 on the sensitivity of parental (HeLa) and cisplatin-resistant (HeLa/CP) human cervical carcinoma cells 
to cisplatin. Cells were treated without (open circle) or with 1 μM (black square), 2 μM (black triangle) or 3 μM (black circle) NSC109268 and varying 
concentrations of cisplatin for 72 h. Cell survival was determined by the MTT assay. The control values were based upon the results obtained in the 
absence of any drug but in the presence of vehicle or NSC109268. Each value represents the mean ± SD of four determinants from a single microtiter 
plate. The results are representative of three independent experiments.
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Discussion
Cisplatin has been very effective for the treatment of
gynecological cancers, such as ovarian and cervical can-
cers. However, the development of resistance in initially
responsive tumors to cisplatin is a major obstacle in cispl-
atin-based therapy. We inadvertently discovered that
NSC109268 sensitizes budding yeast Saccharomyces cere-
visiae to cisplatin [11]. The results of our present study
demonstrate that cisplatin-resistant ovarian cancer 2008/
C13* cells are exquisitely sensitive to combined treatment
with NSC109268 and cisplatin. We have utilized three
independent methods to assess the effects of NSC109268
on cisplatin sensitivity-MTT assay, PARP cleavage and
Yo-Pro-1/PI staining. Using all three assays, we have
found that NSC109268 had a greater effect in augmenting
the sensitivity of cisplatin-resistant 2008/C13* cells to cis-
platin compared to its drug-sensitive counterpart.
Most of the anticancer drugs kill cancer cells by induc-
ing apoptosis and a defect in apoptotic signaling could
contribute to drug resistance. p53 plays a critical role in
eliciting cellular responses to DNA damage, and is fre-
quently mutated in ovarian cancers [12,13]. It has been
reported that the status of p53 is an important determi-
Figure 4 Effect of NSC on p53 induction and cleavage of PARP. Cells were treated with or without 2 or 3 μM NSC109268 and 1 μM (2008) or 40 
μM cisplatin (2008/C13*) for 24 h or 48 h. Western blot analysis was performed with total cell lysates using indicated antibodies. Actin was used to 
control for loading differences.
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Figure 5 Effect of NSC on cisplatin-induced cell death. Cells were 
treated with or without 2 or 3 μM NSC109268 and 1 μM (2008) or 40 
μM cisplatin (2008/C13*) for 48 h. Following incubation, cells were 
stained with Yo-Pro-1 and PI as described in the Methods. Fluorescent 
staining was visualized using Zeiss Axiovert 40 inverted microscope.
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Figure 6 Effect of p53 knockdown on cisplatin sensitization by 
NSC109268. Cells were transfected with or without control non-tar-
geting siRNA or p53 siRNA as described under Methods. Cells were 
then treated with or without 2 μM NSC102968 and 40 μM cisplatin. A, 
Western blot analysis was performed with total cell lysates as de-
scribed under legend to Figure 4. B, Cells were stained with Yo-Pro-1 
and PI as described under legend to Figure 5.
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nant of cisplatin sensitivity in patients with ovarian can-
cer [14-16] although some studies suggest that cisplatin-
induced cell death is independent of the presence of wild-
type p53 [17]. An aberration in p53 has also been impli-
cated in cisplatin resistance [11,18-20]. Introduction of
wild-type p53 by adenovirus vector sensitized ovarian
cancer cells to cisplatin [21-23]. In the present study, we
have used ovarian cancer 2008 cells and its cisplatin-
resistant variant 2008/C13* cells which contain wild-type
p53. Cisplatin caused induction of p53 in both parental
and cisplatin-resistant 2008 cells and the increase in p53
correlated with cisplatin-induced apoptosis (Figure 3). In
addition, sensitization of 2008/C13* cells by NSC109268
was associated with an increase in p53 level (Figure 4).
Furthermore, NSC109268 failed to sensitize parental and
cisplatin-resistant HeLa cells in which p53 is degraded by
the human papilloma virus E6 (Figure 2). These results
are consistent with the notion that NSC109268 sensitizes
ovarian cancer 2008 cells to cisplatin via p53-dependent
mechanisms. Following observations, however, argue
against the involvement of p53 in the potentiation of cis-
platin sensitivity by NSC109268.
Although little p53 could be detected in parental HeLa
cells, we have found that p53 is detectable in HeLa/CP
cells and it is further increased by the treatment with cis-
platin [24]. Perhaps low level of cisplatin-induced DNA
damage during the selection of HeLa/CP cells stabilizes
p53. We have also found that the level of HPV E6 protein,
which degrades p53 is less in HeLa/CP cells [24]. To
determine if p53 is responsible for cisplatin sensitization
by NSC109268, we depleted endogenous p53 by siRNA
silencing. Knockdown of p53 had little effect on cell death
by cisplatin or combination of NSC109268 and cisplatin
(Figures 6A and 6B). Interestingly, depletion of p53
appears to increase cisplatin-induced cell death in 2008/
C13* cells (Figure 6B). These results are consistent with
earlier reports that inactivation of p53 may enhance sen-
sitivity of cisplatin-resistant ovarian cancer cells to cispla-
tin [25].
The effect of NSC109268 on cisplatin sensitivity
depends both on the concentrations and duration of
exposure to these compounds. While a 24 h treatment
with 3 μM NSC109268 alone had little effect on cell sur-
vival, a 72 h treatment with ≥ 3 μM NSC109268 caused a
substantial decrease in cell growth as determined by the
MTT assay (data not shown). The effect of NSC109268
on cell growth inhibition was much more pronounced in
2008/C13* cells compared to 2008 cells [11]. In both yeast
and ovarian cancer cells, NSC109268 appears to inhibit
progression of cells from the S phase to G2/M phase [11].
Thus, cells arrested at the S phase may be more sensitive
to cisplatin. Additionally, we have found that in response
to cisplatin, a substantial fraction of 2008/C13* cells were
stained with the cell impermeable dye propidium iodide.
Since these cells are resistant to apoptosis, it is conceiv-
able that NSC109268 increased cisplatin-induced cell
death by enhancing cisplatin-induced necrosis via p53-
independent pathway.
The mechanisms of cisplatin resistance are multifacto-
rial and include decrease in drug uptake, increase in DNA
repair, increase in cellular thiol content, defect in p53 and
increase in antiapoptotic signaling [26]. The protein
kinase C (PKC) signaling pathway plays an important role
in determining cisplatin sensitivity [27,28]. Activators of
PKC sensitized both 2008 [28] and HeLa cells [27] to cis-
platin. Furthermore cisplatin resistance was associated
with increase in novel PKC and decrease in conventional
PKC [29,30]. It remains to be seen if NSC109268 influ-
ences the PKC signaling pathway.
NSC109268 may also increase cisplatin sensitivity by
facilitating its uptake or decreasing repair of cisplatin-
induced DNA damage. Although cisplatin is believed to
enter cells via passive diffusion, it has been reported that
a fraction of cisplatin enters cells via the plasma mem-
brane copper transporter CTR1 [31,32]. Following inter-
nalization, both copper and cisplatin were shown to cause
downregulation of CTR1 in ovarian cancer cells by the
proteasome-mediated pathway [33]. NSC109268 con-
tains two copper ions and it was shown to inhibit 20S
proteasome [34]. Since loss of CTR1 can contribute to
cisplatin resistance [32], it is conceivable that NSC109268
inhibits degradation of CTR1 by cispatin resulting in
higher intracellular levels of cisplatin and consequently
increase in cisplatin-induced cell death. Future studies
should determine how NSC109268 attenuates cisplatin
resistance via p53-independent mechanisms. Neverthe-
less, the observation that NSC109268 can partially over-
come cisplatin resistance is significant. Since NSC
compound can be easily synthesized, it could be used as
an adjuvant to cisplatin-based therapy.
Conclusions
The present study demonstrates that NSC109268
enhances the sensitivity of cisplatin-resistant ovarian
cancer 2008/C13* cells to cisplatin. While the induction
of p53 by cisplatin or combination of NSC109268 and cis-
platin correlates with increased cellular sensitivity to cis-
platin, knockdown of p53 had no effect on cisplatin
sensitization by NSC109268. Thus, NSC109268 potenti-
ates cisplatin sensitivity via p53-independent mecha-
nism(s). NSC109268 can be used in combination with
cisplatin to circumvent cisplatin resistance.
Methods
Materials
Cisplatin, MTT and monoclonal antibody to actin were
purchased from Sigma (St. Louis, MO). Monoclonal anti-
bodies to p53 and GAPDH were from Santa Cruz Bio-Shankar et al. Journal of Molecular Signaling 2010, 5:4
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technology, Inc. (Santa Cruz, CA), and monoclonal
a n t i b o d i e s  t o  P A R P  a n d  p 5 3  w e r e  o b t a i n e d  f r o m
Pharmingen (San Diego, CA). siRNA SMARTpool against
p53, and non-targeting SMARTpool siRNA were
obtained from Dharmacon (Lafayette, CO). Horseradish
peroxidase-conjugated goat anti-mouse and donkey anti-
rabbit antibodies were obtained from Jackson Immu-
noResearch Laboratories, Inc. (West Grove, PA). Polyvi-
nylidene difluoride membrane was from Millipore
(Bedford, MA), and enhanced chemiluminescence detec-
tion kit was from Amersham (Piscataway, NJ). Lipo-
fectamine 2000 transfection reagent and YO-PRO-1 were
obtained from Invitrogen (Carlsbad, CA). Propidium
Iodide was purchased from Molecular Probes (Eugene,
OR). NSC109268 was provided by the Developmental
Therapeutics Branch of the National Cancer Institute,
and was also custom-synthesized by Omm Scientifc, Dal-
las, TX.
Cell Culture
Human ovarian cancer 2008 cells and cisplatin-resistant
variant 2008/C13* cells developed by Dr. Stephen B.
Howell were obtained from the University of California
San Diego. Cells were maintained in RPMI 1640 supple-
mented with 5% heat-inactivated FBS and 2 mmol/L glu-
tamine. Human cervical carcinoma HeLa cells and its
cisplatin-resistant variants (HeLa/CP) [35] were main-
tained in DMEM supplemented with 10% heat-inacti-
vated fetal bovine serum and 2 mmol/L glutamine. Cells
were kept in a humidified incubator at 37°C with 95% air
and 5% CO2.
Assessment of cell viability by MTT Assay
Exponentially growing cells were plated in microtiter
plates and incubated at 37°C in 5% CO2. The following
day, cells were pretreated with or without NSC109268
and cisplatin as indicated in the text. The number of via-
ble cells was determined using the dye MTT as previously
described (5).
Assesment of cell death by YO-PRO-1/propidium iodide (PI) 
assay
Cells were labeled with 0.5 μM Yo-Pro-1 and 2 μM PI and
incubated at 37°C for 15 min. Labeling of the cells was
visualized using a Zeiss Axiovert 40 inverted microscope
with the AxioVision Rel 4.6 software (Zeiss, Göttingen,
Germany).
Immunoblot analysis
Equivalent amounts of protein from total cellular extracts
were electrophoresed by SDS-PAGE and transferred elec-
trophoretically to a poly(vinylidene difluoride) mem-
brane. Immunoblot analyses were performed as
described previously [36].
Knockdown of p53 by siRNA
Control siRNA or siRNA targeted against p53 were intro-
duced into cells using Lipofectamine 2000 (Invitrogen)
and manufacturer's protocol as previously described [37].
B r i e f l y ,  c e l l s  w e r e  s e e d e d  o n e  d a y  b e f o r e  t r a n s f e c t i o n .
Forty-eight hour following siRNA transfection, cells were
treated with NSC109268 and cisplatin as indicated in the
text and processed for Western blot analysis.
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